Drug intelligence / Profile preview

Parakef

Development stage: Unknown
Lead developer: Bennet Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**Parakef** is an oral fixed-dose cold-relief tablet marketed by Bennet Pharmaceuticals in India. It contains **paracetamol 350 mg**, **caffeine 30 mg**, and **chlorpheniramine maleate 4 mg**. Paracetamol provides analgesic and antipyretic activity, chlorpheniramine is a sedating first-generation histamine H1-receptor antihistamine that relieves allergic symptoms such as rhinorrhea, sneezing, and watery eyes, and caffeine is included as an analgesic adjuvant. The product is marketed for symptomatic treatment of the common cold.

Brand names: ParakefParakef Tablet

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Parakef.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parakef.

Explore the full profile